the Future of Immune Reprogramming and Monitoring ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­
stocksearning
A message from Interactive Offers


This innovation platform is commercializing promising biotechnologies with focus on monitoring and modulating the immune system.

The pandemic has exposed systemic weaknesses in global health systems, emphasizing the urgent need for robust, resilient health infrastructure. And this company might just be one of the few that has responded to this need.

This public life sciences company is on a mission to accelerate innovative businesses to address the most pressing health challenges.

Some of its current and potential programs and subsidiaries include:
  • Adimune- A pre-clinical stage company that develops immune modulation therapies to advance immune health by naturally restoring immune tolerance.
  • Pearsanta- A commercial-stage company developing precision diagnostic technologies. Their proprietary platforms include - Mitomic® and Flow Cytometry technologies.
  • Women’s Health (Proposed Acquisition)- A US biopharma company, which commercializes innovative products to address unmet needs in women’s health.
  • Public Health (Proposed Acquisition)- This is a commercial-stage company with a mission to advance the treatment of infectious diseases.

By acquiring disruptive, innovative, and scalable companies that are positioned for immense growth in targeted markets, this biotech is one to watch.

To read more about its diverse, robust pipeline, click here now.

This message is a PAID ADVERTISEMENT for Aditxt, Inc. (ADTX) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $10,000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships, SMS Sends, and Banner Display Ads between September 30, 2024 and October 4, 2024. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Aditxt, Inc. (ADTX) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Aditxt, Inc. (ADTX) on Aditxt website for additional information about the relationship between Interactive Offers and Aditxt, Inc. (ADTX).

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com